Please ensure Javascript is enabled for purposes of website accessibility

New Coronavirus Antigen Test Earns Emergency Authorization from FDA

By Cory Renauer - May 10, 2020 at 12:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA is working through the weekend to boost the availability of rapid COVID-19 testing.

Government regulators are working through the weekend to boost public health officials' ability to monitor for local COVID-19 outbreaks. On Saturday, the U.S. Food and Drug Administration issued its first emergency use authorization (EUA) for a COVID-19 antigen test. The Sofia 2 SARS Antigen FIA from Quidel (QDEL) is now authorized for use in laboratories and at the point of care.  

Another first

The FDA has already approved diagnostics that look for genetic material specific to SARS-CoV-2, and tests that look for the antibodies immune systems produce in response to the virus. The Sofia 2 SARS Antigen FIA is the first that looks for chunks of the virus itself -- and it does so really fast.

Laboratory assay close up

Image source: Getty Images.

Quidel's test can scan a sample in 15 minutes for antigens, and unlike antibody tests, antigen tests rarely produce false positives. Molecular diagnostics are generally more sensitive, but they take much longer to run, with the exception of Abbott's (ABT 0.90%) increasingly popular ID NOW platform. Abbott's point-of-care coronavirus test can amplify genetic material for analysis without a long incubation process.

Room for all

Considering the dearth of available testing in the U.S. at the moment, Quidel probably won't have any trouble carving out a significant share of an enormous market. A low single-digit percentage of tests returning positive suggests enough people are being tested to prevent further outbreaks while returning to some level of normalcy. The national percentage is falling, but 13.2% of samples sent to public and commercial laboratories tested positive last week.

More than a few healthcare providers already use Quidel's Sofia 2 system to quickly test patients for influenza, Lyme disease, and respiratory syncytial virus. In addition to rapid results, the Sofia 2 system also connects to the company's data management system. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Quidel. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Quidel Corporation Stock Quote
Quidel Corporation
QDEL
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$111.48 (0.90%) $0.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.